News

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

Erivedge Approved to Treat Basal Cell Carinoma

January 31, 2012

Erivedge (vismodegib) has been approved by the U.S. Food and Drug Administration to treat the most common form of skin cancer, basal cell carcinoma, the agency said Monday.
 

Antiretroviral Medications Linked to Cleft Deformities

January 31, 2012

Drugs to keep HIV-infected women from transmitting virus to fetus may trigger cleft defects.
 

Education Reduces Distress During Breast Cancer Treatment

January 31, 2012

Physical, emotional, and social adjustment occurs over time with or without interventions
 

Connected nodes in throat cancer signal poor prognosis

January 31, 2012

The presence of "matted" lymph nodes (nodes connected together) in persons with oropharyngeal squamous cell carcinoma was associated with 3-year survival of 69% rather than 94%.
 

Parabens found in breast tumor tissue of nonusers of underarm products

January 30, 2012

Chemicals known as parabens, which may have a role in breast cancer and are commonly used as preservatives in cosmetics, food products, and pharmaceuticals, have now been found in measurable levels in the breast tissue of women who do not use underarm products.
 

Drug Approved for Advanced Kidney Cancer

January 27, 2012

Inlyta has been approved by the FDA to treat advanced renal cell carcinoma in patients who haven't responded to another drug.
 

Comparable Clinical Activity for Low-, High-Dose Clofarabine

January 27, 2012

More adverse effects seen for high dose in patients with higher-risk myelodysplastic syndrome
 

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions